Antibodies

Lecanemab: a review

Lecanemab: drawbacks to consider

Lecanemab vs aducanumab

FDA approval of lecanemab: what does the data tell us about the amyloid hypothesis?

Highlights from CTAD 2022

Meta-analysis of the latest anti-amyloid immunotherapies: benefit vs risk

First-in-human clinical trial of the anti-PD-L1 antibody, IBC-Ab002, in early AD

Future direction for anti-amyloid immunotherapies

Lecanemab and what this means for the future treatment of Alzheimer’s disease

Is amyloid load a valid surrogate endpoint for AD clinical trials?

The Phase III NILEAD trial: nilotinib as a novel treatment for AD

TOGETHER study: updates on bepranemab as a potential treatment for AD

Potential benefits of an anti-Aβ vaccine over monoclonal antibodies

Aducanumab updated monitoring recommendations for amyloid-related imaging abnormalities (ARIA)

Updates in pharmacological treatment of Alzheimer’s disease: lecanemab, donanemab and gantenerumab

Is amyloid lowering still a valid approach in Alzheimer’s disease?